Skip to main content

Advertisement

Table 1 Baseline socio-demographic and clinical characteristics of 58 larynx-hypopharynx cancer patients, according to regular antiplatelets use

From: Lower platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma: a retrospective analysis

  Non-Antiplatelets users Antiplatelets users Fisher exact test
  N (%) n (%)
Sex
 Men 34 (89.5) 16 (80.0) p = 0.43
 Women 4 (10.5) 4 (20.0)  
Age (years)
 <65 28 (73.7) 5 (25.0) p <0.01
 ≥65 10 (26.3) 15 (75.0)  
Tobacco smoking
 Never 5 (13.2) 4 (20.0) p = 0.70
 Ever 33 (86.8) 16 (80.0)  
T status
 T2–T3 27 (71.0) 20 (100.0) p = 0.01
 T4 11 (29.0) 0 (0.0)  
N status
 N0 11 (29.0) 8 (40.0) p = 0.56
 N1–N3 27 (71.0) 12 (60.0)  
Stage
 III 13 (34.2) 15 (75.0) p <0.01
 IV 25 (65.8) 5 (25.0)  
Platelet count at radiotherapy beginning (cells/μL)
 <250.000 19 (51.3) 11 (57.9) p = 0.78
 ≥250.000 18 (48.7) 8 (42.1)  
Locoregional recurrence
 No 17 (44.7) 16 (80.0) p = 0.01
 Yes 21 (55.3) 4 (20.0)